Gene · 79679
Papers2,409
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
521 to 540 of 2,409
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer. | Sci Rep | 2023 | 36646765 | PubTator, text mining | PubMed |
| Integrated analysis of single-cell RNA-seq and bulk RNA-seq unveils heterogeneity and establishes a novel signature for prognosis and tumor immune microenvironment in ovarian cancer. | J Ovarian Res | 2023 | 36642706 | PubTator, text mining | PubMed |
| New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads. | Clin Cancer Res | 2023 | 36637483 | PubTator, text mining | PubMed |
| Humanized mouse models for immuno-oncology research. | Nat Rev Clin Oncol | 2023 | 36635480 | PubTator, text mining | PubMed |
| ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target. | Theranostics | 2023 | 36632213 | PubTator, text mining | PubMed |
| Cell Pair Algorithm-Based Immune Infiltrating Cell Signature for Improving Outcomes and Treatment Responses in Patients with Hepatocellular Carcinoma. | Cells | 2023 | 36611994 | PubTator, text mining | PubMed |
| A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma. | BMC Med Genomics | 2023 | 36611208 | PubTator, text mining | PubMed |
| The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma. | J Ovarian Res | 2023 | 36609273 | PubTator, text mining | PubMed |
| Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma. | Int Urol Nephrol | 2023 | 36598731 | PubTator, text mining | PubMed |
| Signaling pathways in brain tumors and therapeutic interventions. | Signal Transduct Target Ther | 2023 | 36596785 | PubTator, text mining | PubMed |
| PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. | J Exp Clin Cancer Res | 2023 | 36588164 | PubTator, text mining | PubMed |
| Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. | Nat Rev Clin Oncol | 2023 | 36418477 | PubTator, text mining | PubMed |
| Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. | Clin Cancer Res | 2023 | 36355054 | PubTator, text mining | PubMed |
| Targeting HER2-positive breast cancer: advances and future directions. | Nat Rev Drug Discov | 2023 | 36344672 | PubTator, text mining | PubMed |
| Predictive biomarkers in gastric cancer. | J Cancer Res Clin Oncol | 2023 | 36260159 | PubTator, text mining | PubMed |
| Identification of senescence-related molecular subtypes and key genes for prostate cancer. | Asian J Androl | 2023 | 36124532 | PubTator, text mining | PubMed |
| Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development. | J Cancer Res Clin Oncol | 2023 | 36038676 | PubTator, text mining | PubMed |
| Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer. | Cancer Immunol Immunother | 2023 | 36002754 | PubTator, text mining | PubMed |
| The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma. | J Cancer Res Clin Oncol | 2023 | 35941227 | PubTator, text mining | PubMed |
| KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy. | J Adv Res | 2023 | 35933091 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/papers?page=27